Table 4.

Relative risk of having gametocytes with the different treatment regimens according to follow-up day, Colombia

Treatment	Day of follow-up
	1	2	3	7	14
	RR (95% CI)*	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)
CQ and SP	1.7 (0.5–5.4)	3.7 (0.9–14.8)	4.6 (1.2–17.9)	11.4 (3.0–43.3)	10.9 (2.9–41.0)
AQ and SP	2.4 (0.8–7.2)	4.76 (1.2–18.4)	5.9 (1.5–22.7)	8.5 (2.2–32.4)	1.0 (0.2–6.8)
MQ and SP	2.0 (0.6–6.1)	4.12 (1.1–16.1)	5.9 (1.5–22.5)	6.2 (1.6–23.7)	5.6 (1.4–21.2)
AS and SP	1.6 (0.5–4.9)	2.6 (0.6–10.3)	2.6 (0.7–10.5)	2.4 (0.6–9.7)	1.8 (0.4–7.5)
AS and AQ	1.1 (0.3–4.0)	1.7 (0.4–7.5)	2.2 (0.5–9.2)	1.4 (0.3–6.6)	0.9 (0.25.0)
AS and MQ	2.4 (0.7–8.3)	2.7 (0.6–12.7)	2.1 (0.4–10.3)	1.0 (0.2–6.8)	1.0
AS, MQ, and PQ†	1.0	1.0	1.0	1.0	–

^*RR = relative risk; CI = confidence interval; CQ = chloroquine; SP = sulfadoxine-pyrimethamine; AQ = amodiaquine; MQ = mefloquine; AS = artesunate; PQ = primaquine. Value in bold are statistically significant.

^†Reference treatment with which other treatments were compared.